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Young normaled young normal hip and spine BMD data from 17 centres across Europe to assess
between centre differences and to compare reference values with the US NHANES-III data. There was strong
evidence of between country heterogeneity, but not between centres within countries. Hip BMDmean values
were lower in Europeanwomen, but SD's differed little from theNHANES-III USA results in both sexes. Itmaybe
necessary to adjust NHANES-III based T-scores by adding/subtracting a country-speciﬁc adjustment factor.
Introduction: It remains unclear whether young normal BMD reference values speciﬁc to an American
population can be validly used for T-score calculation in Europeans.
Methods: We collected population based BMD data from 1163 men and 329 women aged 19-29 years from 17
centres across Europe to comparemean and SD valueswith theNHANES-III studyUSA results. BMD(g/cm2)was
measured at the hip and spine using DXA densitometers cross-calibrated with the European Spine Phantom
(ESP). The only exclusions were for technically inadequate scans. A linear regression model was used to derive
reference values. To allow for direct comparison with published NHANES III study data, the cross-calibrated
BMD values were converted using the ESP equations to Hologic QDR 1000 units.
Results: In men, the overall mean(SD) BMD values expressed in Hologic-QDR1000 units of measurement, were:
femoral neck 0.912(0.132); trochanter 0.793(0.124); and L2-L4 spine 1.027(0.123). The respective estimates in
women were: 0.826(0.115); 0.670(0.093); and 0.983(0.107). However the I2 statistic for heterogeneity indicated
moderate to strong evidence of between-centre heterogeneity. There was, however, no signiﬁcant heterogeneity
observedbetweencentreswithin countries, suggesting that this variationarose fromnational differences. Compared
to theNHANES III population-basedUS data, themean values inwomenwere signiﬁcantly lower at both sites due to
some lower national Europeanmeans. However, at all sites and in both sexes the SD'swere very similar between the
US and Europe. There was some evidence that recruiting volunteers resulted in biased values in women.
Conclusion: Our T-score normal values for the lumbar spine (L2-L4) should be more reliable for spine-speciﬁc risk
assessment than some non-representative normal ranges, and should be evaluated for that purpose in Europe. If T-
scores are tobeused to compare individual datawith ranges seen innormalyoung subjectsof the samenationality, it
may be necessary to adjust femoral NHANES III-based T-scores by adding (or subtracting) a country-speciﬁc
adjustment factor. In risk assessment it is probably sufﬁcient to use NHANES III–based hip T-scores, as supplied for
the hip by densitometermanufacturers, interpreting them in light of recent international meta-analysis data on the
relationship between BMD and fracture risk.
© 2008 Elsevier Inc. All rights reserved.atory, Wort's Causeway, Cambridge CB1 8RN, UK. Fax: +44 1223 741618.
l rights reserved.
333S. Kaptoge et al. / Bone 43 (2008) 332–339IntroductionCurrently there is no population-based reference database for spine
BMD that has won approval for use across all brands of DXA
densitometers. Whether young normal femoral BMD reference values
speciﬁc to the US non-black, non-hispanic population can be validly
used for calculating T-scores in European populations also remains
unclear, even though all brands of densitometers offer the NHANES III
data as referent. Moreover, there is increasing evidence that the
approaches developed to diagnose and treat osteoporosis in women
may be equally useful in men [1]. Therefore with the aim of strength-
ening the approach of using young normal data as DXA reference for
both hip and spine, we assembled young normal BMD data from 1163
male and 329 female participants aged 19-29 years from two multi-
centre population based cohort studies across Europe and from a fur-
ther 4 single-centre population based studies following an extended
call for data in the FP5 Thematic Network in Europe on Male Osteo-
porosis (NEMO).
The two multicentre studies were: a concerted action of the
European Community's COMAC-BME FP2 programme (5 centres) [2,3]
and the Polish EPOLOS osteoporosis study (6 centres). Principal inves-
tigators in Coimbra (Portugal), Ghent (Belgium), Kuopio (Finland),
Prague (Czech Republic), and Odense (Denmark) contributed furtherTable 1
Population-based young normal BMD data contributions by cohort study and centre to the
Study/Centre
(ref)
Country DXA brand Male
Age
Mean
(Range)
Femoral neck
BMD
Trochanter BMD
n Mean (SD) n Mean (SD
COMAC [2,14]
Aberdeen UK Norland XR26 29
(26 - 30)
3 0.991
(0.171)
3 0.835
(0.112)
Leuven Belgium Lunar DPX 24
(22 - 28)
8 0.981
(0.134)
8 0.840
(0.124)
Manchester UK Lunar DPX 28
(27 - 29)
2 1.102
(0.065)
2 0.875
(0.046)
Harrow UK Hologic
QDR1000
26
(24 - 29)
6 1.069
(0.103)
6 0.880
(0.105)
Kuopio Finland Lunar DPX 25
(22 - 30)
12 1.092
(0.219)
12 0.966
(0.203)
Total COMAC 26
(22 - 30)
31 1.050
(0.168)
31 0.898
(0.157)
EPOLOS
wwa1 Poland Lunar DPX 25
(20 - 29)
24 1.009
(0.205)
24 0.813
(0.145)
wwa2 Poland Lunar DPX 25
(22 - 29)
6 0.968
(0.178)
6 0.740
(0.179)
pozn Poland Lunar DPX 25
(20 - 30)
7 1.007
(0.217)
7 0.740
(0.146)
lodz Poland Lunar DPX 24
(20 - 30)
11 0.973
(0.143)
11 0.728
(0.097)
krak Poland Lunar DPX 25
(20 - 29)
11 1.008
(0.135)
11 0.798
(0.113)
wroc Poland Lunar DPX 27
(22 - 30)
9 0.980
(0.138)
9 0.796
(0.124)
Total EPOLOS 25
(20 - 30)
68 0.995
(0.171)
68 0.781
(0.134)
Single centres
Coimbra-JD Portugal Hologic
QDR4500A
24
(19 - 30)
111 0.962
(0.147)
111 0.802
(0.122)
Ghent-JMK Belgium Hologic
QDR4500
28
(24 - 30)
126 0.949
(0.143)
126 0.836
(0.135)
Kuopio-HK
[15]
Finland Lunar DPX 26
(21 - 29)
50 1.047
(0.154)
50 0.902
(0.150)
Prague-JS Czech-
Rep
Hologic
QDR4500A
27
(27 - 27)
1 1.014 (-) 1 0.712 (-)
Odense-KB
[16]
Denmark Hologic
QDR4500A
25
(20 – 30)
776 0.971
(0.160)
776 0.838
(0.144)
Total all
centres
26
(19 - 30)
1163 0.974
(0.159)
1163 0.835
(0.143)population-based young normal BMD data. Young normal non-
population based data was also received from Ghent (Belgium), Paris
(France) and additional centres in the COMAC-BME study.
The ﬁrst aim was to compare the data from different investiga-
tional centres to determinewhether differences in young normal BMD
values at the commonly measured sites of proximal femur and lumbar
spine were related to country of origin or centre. A further aimwas to
compare BMD means and standard deviations (SD's) with the
NHANES III study [4] to determine whether current use of US-derived
T-scores is generally appropriate to European populations.
A subsidiary objective of the studywas to determine the size of any
biasing effect of recruiting volunteer control subjects, since historically
this method has been frequently used to measure the size of the effect
of various bone diseases on BMD.
Subjects and Methods
Subjects
The principal group of population-based subjects (Table 1) were all selected from age-
sex registers such as complete population listings, voter lists, or primarymedical care lists
of patients in countries with comprehensive health services and were approached by
letter or telephone. Each subject was asked to attend once for a densitometry measure-
ment of the hip and/or spine and height and weight measurement. Each centre had ﬁrst
received ethics permission to proceed with their study from their local Research EthicsNEMO collaboration
Female
L2-L4 Spine BMD Age
Mean
(Range)
Femoral neck
BMD
Trochanter BMD L2-L4 Spine
BMD
) n Mean (SD) n Mean (SD) n Mean (SD) n Mean (SD)
3 1.011
(0.103)
- - - - - - -
8 1.167
(0.131)
23
(20 - 28)
15 1.024
(0.161)
15 0.789
(0.144)
15 1.250
(0.143)
2 1.290
(0.053)
- - - - - - -
6 1.305
(0.173)
25
(21 - 30)
8 0.921
(0.172)
8 0.773
(0.074)
8 1.228
(0.156)
12 1.243
(0.165)
23
(21 - 27)
10 0.934
(0.177)
10 0.774
(0.155)
10 1.163
(0.090)
31 1.216
(0.164)
24
(20 - 30)
33 0.972
(0.170)
33 0.781
(0.131)
33 1.218
(0.134)
24 1.104
(0.151)
25
(20 - 30)
65 0.894
(0.117)
65 0.686
(0.102)
65 1.070
(0.103)
6 1.018
(0.145)
27
(23 - 30)
6 0.833
(0.135)
6 0.620
(0.047)
6 1.006
(0.067)
7 0.993
(0.104)
26
(22 - 29)
10 0.977
(0.173)
10 0.727
(0.060)
10 1.027
(0.088)
11 1.043
(0.162)
24
(20 - 30)
28 0.942
(0.136)
28 0.683
(0.093)
28 1.058
(0.164)
11 1.044
(0.070)
24
(20 - 30)
11 0.909
(0.073)
11 0.691
(0.060)
11 1.038
(0.117)
8 1.072
(0.139)
26
(21 - 30)
10 0.891
(0.117)
10 0.698
(0.113)
10 1.092
(0.106)
67 1.061
(0.137)
25
(20 - 30)
130 0.909
(0.126)
130 0.687
(0.094)
130 1.060
(0.118)
111 1.039
(0.136)
24
(19 - 30)
166 0.825
(0.114)
166 0.684
(0.099)
166 1.024
(0.113)
126 1.124
(0.145)
- - - - - - -
50 1.208
(0.125)
- - - - - - -
- - - - - - - - -
777 1.115
(0.149)
- - - - - - -
1162 1.112
(0.150)
25
(19 - 30)
329 0.873
(0.135)
329 0.695
(0.105)
329 1.058
(0.130)
334 S. Kaptoge et al. / Bone 43 (2008) 332–339Committee according to the Declaration of Helsinki. The non-population-based subjects
were recruited as described in Table 2, again according to the Helsinki Declaration.
DXA Procedures
Femoral neck, trochanter, and/or L2-L4 spine BMD were measured according to the
manufacturer's instructions with either pencil beam or fan beam densitometers made by
three manufacturers (Hologic, Lunar, and Norland). Each centre followed manufacturers'
procedures to check the stability and accuracy of their equipment using regular (daily)
measurements of the manufacturer's phantom. When measurements were inadvertently
made during times of equipment malfunction, the data was excluded from this analysis.
Because the three brands do not give the same results while expressing their BMD
results in the units of g/cm2 it was necessary to cross-calibrate them using the European
Spine Phantom (ESP). This was done as described by Pearson et al. [3], Kalender et al.
[5], and Lunt et al. [6]. Theminimum acceptable data for inclusion in the study was BMD
at one measurement site (from femoral neck, trochanter, or L2-L4 spine), age, weight,
and height at/or near the scan date.
Supplementary analyses were conducted using universally standardised BMD
values (sBMD) [7,8] to assess the extent to which sBMD accounted for between-centre
differences in mean BMD values attributable to different DXA manufacturer-brands
used in the centres (Hologic, Lunar, Norland). Since the use of phantom data for
universal standardisation has been found to be imprecise compared to using human
data [7–9], in principle universal standardisation requires that a random sample of
participants have their BMD measured using all the densitometers in the study [7,8],
which was not possible in a retrospective meta-analysis. Thus instead, we ﬁrst
estimated the mean ESP cross-calibration parameters for each DXA brand using
published mean BMD values from measurements of the ﬁrst 30 ESP's on each DXA
brand [5]. We then used these brand-speciﬁc mean ESP parameters to convert each
participant's ESP-standardised BMD value into equivalent BMD estimates as expected
from measurements using other DXA brands. Then we applied the optimal universal
standardisation procedure of Hui L et al [8] to generate sBMD values. In keeping with
previous convention for reporting, the sBMD results are reported in mg/cm2 units.
Statistical analysis
Between-centre differences inweight and height adjusted mean BMD levels and trends
with age were assessed using analysis of variance (ANOVA)/linear regression models. The
same models were used to derive age and sex speciﬁc reference ranges for the ESP-
standardised BMD values. Due to small numbers in some centres, the primary analyses were
donewith the centres combined bycountry. To enable a comparisonwithNHANES 3US data,
all the ESP standardised BMD values were transformed to Hologic QDR 1000W equivalents
using ESP cross-calibration parameters [10]. Comparison was then made with the young
normal values published by the NHANES III study [4].Table 2
Non population-based young normal BMD data contributions by cohort study and centre to
Study/Centre
(ref)
Country DXA brand Male
Age
Mean
(Range)
Femoral neck
BMD
Trochanter B
n Mean (SD) n Mean
COMAC [2,14]
Madrid Spain Hologic
QDR1000
27
(24 - 30)
- - - -
Hvidore Denmark Norland XR26 - - - - -
Amsterdam Netherlands Norland XR26 28
(27 - 29)
3 1.000
(0.067)
3 0.917
(0.037
Bern Switzerland Hologic
QDR1000
- - - - -
Rotterdam-C Netherlands Lunar DPX 26
(21 - 30)
4 0.912
(0.139)
4 0.782
(0.095
Wurzburg Germany Lunar DPX 27
(21 - 30)
11 0.949
(0.175)
11 0.796
(0.147)
Total COMAC 27
(21 - 30)
18 0.949
(0.151)
18 0.813
(0.130)
Single centres
Ghent-
confam
Belgium Hologic
QDR2000
24
(13 - 30)
20 0.939
(0.173)
20 0.808
(0.158)
Ghent-
conpro
Belgium Hologic
QDR2000
24
(19 - 29)
41 0.948
(0.129)
41 0.817
(0.131)
Ghent-sons Belgium Hologic
QDR1000+
25
(22 - 29)
52 1.056
(0.163)
52 0.910
(0.158)
Paris-MC France Lunar DPXL 25
(19 - 30)
27 0.927
(0.133)
26 0.791
(0.109)
Total all
centres
25
(13 - 30)
158 0.979
(0.158)
157 0.842
(0.147)Prior to the main analysis a check was done to investigate possible effects on BMD
in Europe of using volunteer recruits, as has been common in the published literature. A
nested ANOVA model was used to test whether on average there was a statistically
signiﬁcant difference in the mean BMD value for population-based vs. non-population
based centres relative to variation between centres under the same classiﬁcation (i.e.
centres nested within recruitment method) adjusted for age, weight, and height.
Differences in variance of BMD in the population-based vs. non-population based
centres was assessed using Levene's test for equality of variance. Each sex was analysed
separately.
Overall mean BMD across the centres was determined by pooling the adjusted
centre-speciﬁc mean BMD values using random effects meta-analysis, which weights
the contribution of each centre by the inverse of the variance of its estimated mean
BMD plus estimated between centre variance (τ2, tau2) in BMD. Therefore, the pooled
estimate is less likely to be biased towards results from large centres in the presence of
signiﬁcant heterogeneity (τ2N0) between centres. The extent of heterogeneity in mean
BMD levels across centres was tested using Cochran's Q statistic, calculated as the sum
of squared differences between each centre's adjusted mean BMD and the overall mean
BMD weighted by the information provided by each centre [11]. Under the null
hypothesis of no heterogeneity, the Q statistic follows a chi-square distribution with
degrees of freedom equal to the total number of centres less 1 and provides a formal
statistical test of signiﬁcance of heterogeneity. The Q statistic was supplemented by the
I2 statistic for quantifying the impact of heterogeneity[11]. I2 values range between 0%
to 100% and represent the proportion of variation in the overall pooled estimate that is
attributable to true between centre heterogeneity rather than chance. The centres were
further sub-grouped by country to assess the extent to which the heterogeneity could
be explained by country. Finally, centres with less than 10 subjects recruited were
excluded and the data re-analysed to check that the random-effects modelling strategy
had effectively adjusted for centre size in calculating means, SDs, and inter-country
heterogeneity.
Results
For the men there was no signiﬁcant effect of recruitment method,
with the BMD difference between population-based vs. non-popula-
tion based classiﬁcations being: femoral neck (-0.004 g/cm2, P=0.32,
n=1320); trochanter (-0.018 g/cm2, P=0.89, n=1319) and L2-L4 spine
(-0.011 g/cm2, P=0.99, n=1222). However for the women, while the
difference between groups was not signiﬁcant at the femoral neck or
trochanter (mean differences 0.094 and 0.020 g/cm2, p=0.49 and 0.11
respectively, n=367), signiﬁcant differences emerged at the L2-L4
spine measurement site (0.111 g/cm2 p=0.01, n=390). Therefore, thethe NEMO collaboration
Female
MD L2-L4 Spine
BMD
Age
Mean
(Range)
Femoral neck
BMD
Trochanter
BMD
L2-L4 Spine
BMD
(SD) n Mean (SD) n Mean (SD) n Mean (SD) n Mean (SD)
11 1.257
(0.118)
27
(23 - 29)
- - - - 13 1.249
(0.118)
- - 25
(21 - 29)
2 0.978
(0.187)
2 0.812
(0.113)
11 1.194
(0.120)
)
3 1.048
(0.083)
25
(22 - 30)
6 0.994
(0.192)
6 0.812
(0.187)
6 1.258
(0.082)
- - 26
(21 - 29)
11 1.000
(0.068)
11 0.831
(0.049)
11 1.328
(0.118)
)
4 1.140
(0.162)
25
(23 - 29)
4 0.889
(0.089)
4 0.714
(0.084)
5 1.244
(0.121)
11 1.055
(0.159)
25
(21 - 30)
15 0.928
(0.113)
15 0.710
(0.097)
15 1.143
(0.132)
29 1.143
(0.163)
26
(21 - 30)
38 0.958
(0.119)
38 0.767
(0.114)
61 1.228
(0.131)
- - - - - -
- - - - - -
- - - - - -
31 1.076
(0.163)
- - - -
60 1.108
(0.165)
26
(21 - 30)
38 0.958
(0.119)
38 0.767
(0.114)
61 1.228
(0.131)
335S. Kaptoge et al. / Bone 43 (2008) 332–339primary report is on the population-based data. There was no
signiﬁcant difference in the residual variance for BMD measurements
at the three sites in the population-based centres vs. non-population
based centres in either sex (pN0.19).Fig. 1. ESP standardised femoral neck BMD means and 95% CIs for each country represented.
and (d) females. Centremeans were adjusted formen to age 26y, weight 80 kg, and height 181
country indicate participant numbers. Country effects for population-based data: pb0.0001Figs. 1 and 2 show the effects of country and centres within country
on mean femoral neck and L2-L4 spine BMD respectively, with age,
weight, and height adjusted to their overall mean values in the
combined data. There was signiﬁcant between centre heterogeneity inTop: Population-based data for (a) males and (b) females; bottom: all data for (c) males
cm and for women to age 25y, weight 59 kg, and height 164 cm; The numbers after each
in men and p=0.004 in women; for combined data pb0.0001 for both sexes.
336 S. Kaptoge et al. / Bone 43 (2008) 332–339the adjusted mean BMD levels for the population-based centres in both
genders (Figs.1 & 2 and Supplementary Table 1). The %weight column in
Figs. 1 and 2 shows the weight as a proportion assigned to each centre/Fig. 2. ESP standardised L2-L4 BMD means and 95% CIs for each country represented. Top:
(d) females; (the right shift in the overall mean value for females in the all data plot was due t
adjusted for men to age 26y, weight 80 kg, and height 181 cm and for women to age 25y, w
numbers. Country effects for all data shown: pb0.0001.country by the random effects meta-analysis method when calculating
the overall mean value, and it accounts for both the precision of the
meanvalue for each centre aswell as estimated between centre/countryPopulation-based data for (a) males and (b) females; bottom: all data for (c) males and
o the statistically signiﬁcant effect of recruitment method – see text). Centremeans were
eight 59 kg, and height 164 cm; The numbers after each country indicate participant
Table 3
Summary of pooled mean value and statistics quantifying heterogeneity between centres and between countries in universally standardised young normal population-based BMD
values at the femoral neck, trochanter and L2-L4 spine in males and females adjusted for age, weight, and height
Using data from all population-based centres Excluding centres with b10 participants
Grouping factor /
BMD region
Number of
groups
Random effects
pooled mean
(95% CI)
Between-
group SD τ a
Q statistic
χ2 (df)
p I2
(95% CI)
Random effects
pooled Mean
(95% CI)
Between-
group SD τ a
Q statistic
χ2 (df)
P I2
(95% CI)
By centre
Male
Femoral neck 15 1014
(992, 1036)
29 48 (14) b0.0001 71%
(50%, 83%)
1007
(983, 1031)
27 33 (7) b0.0001 79%
(58%, 89%)
Trochanter 15 867
(846, 889)
29 50 (14) b0.0001 72%
(53%, 83%)
871
(846, 896)
30 41 (7) b0.0001 83%
(68%, 91%)
L2-L4 spine 15 1111
(1085, 1137)
39 84 (14) b0.0001 83%
(74%, 89%)
1110
(1082, 1138)
35 56 (7) b0.0001 88%
(78%, 93%)
Female
Femoral neck 10 930
(897, 962)
45 55 (9) b0.0001 84%
(71%, 91%)
928
(882, 974)
48 50 (4) b0.0001 92%
(84%, 96%)
Trochanter 10 746
(729, 764)
18 19 (9) 0.022 53%
(5%, 77%)
735
(721, 748)
8 6 (4) 0.235 28%
(0%, 72%)
L2-L4 spine 10 1080
(1049, 1111)
43 59 (9) b0.0001 85%
(74%, 91%)
1070
(1035, 1106)
36 31 (4) b0.0001 87%
(72%, 94%)
By country
Male
Femoral neck 6 1005
(978, 1032)
29 35 (5) b0.0001 86%
(71%, 93%)
1001
(975, 1028)
27 31 (4) b0.0001 87%
(72%, 94%)
Trochanter 6 871
(843, 898)
30 40 (5) b0.0001 87%
(75%, 94%)
870
(843, 897)
28 34 (4) b0.0001 88%
(76%, 95%)
L2-L4 spine 6 1111
(1078, 1144)
37 61 (5) b0.0001 92%
(85%, 96%)
1107
(1074, 1139)
35 53 (4) b0.0001 92%
(85%, 96%)
Female
Femoral neck 5 926
(879, 972)
47 46 (4) b0.0001 91%
(83%, 96%)
922
(861, 982)
51 46 (2) b0.0001 96%
(91%, 98%)
Trochanter 5 757
(733, 782)
21 15 (4) 0.004 74%
(35%, 90%)
738
(718, 757)
13 5 (2) 0.068 63%
(0%, 89%)
L2-L4 spine 5 1110
(1064, 1156)
47 56 (4) b0.0001 93%
(86%, 96%)
1082
(1033, 1130)
40 30 (2) b0.0001 93%
(84%, 97%)
aThis estimate of the between-group standard deviation (τ) provides a means of calculating the expected range of mean values across centres/countries, for example, the pooled
mean femoral neck sBMD in males was 1014 mg/cm2 and as shown above τ=29, from which the 95% range of mean BMD values for individual centres would be estimated to be
1014±1.96⁎29 or 957 to 1071 mg/cm2.
337S. Kaptoge et al. / Bone 43 (2008) 332–339heterogeneity summarised in Supplementary Table 1. The estimate of
the between centre/country standard deviation (τ) provides a means of
calculating the expected range of mean values across centres/countries,
for example, from Fig.1 (a) the pooledmean femoral neck BMD inmales
was 1.01 g/cm2 and Supplementary Table 1 shows that τ=0.035, from
which the 95% range of mean BMD values for individual centres would
be estimated to be 1.01±1.96⁎0.035 or 0.94 to 1.08 g/cm2. There was
moderate to high heterogeneity between centres, with the I2 statistic in
males being 70% at the femoral neck and 83% at the L2-L4 spine. In
females the I2 estimates were 84% at the femoral neck and 53% for L2-L4
spine. Similar levels of heterogeneitywere observed for trochanter BMD
with the I2 statistic being 72% in men and 91% in females (Supplemen-
tary Table 1). There was no signiﬁcant heterogeneity in BMD levels for
centreswithin the same countryat the femoral neck and trochanter sitesTable 4
Comparison of European femoral neck and trochanter BMD data with US NHANES III data
Sex/ BMD region European Data (current study) US NHANES III d
n Mean BMD g/cm2 (95% CI) SD n Mean BM
Male
Femoral neck 1163 0.912 (0.904, 0.920) 0.132 382 0.93 (0.9
Trochanter 1163 0.793 (0.786, 0.800) 0.124 382 0.78 (0.7
L2-L4 spine 1162 1.027 (1.020, 1.034) 0.123 - -
Female
Femoral neck 330 0.826 (0.813, 0.838) 0.115 409 0.86 (0.8
Trochanter 330 0.670 (0.660, 0.680) 0.093 409 0.71 (0.7
L2-L4 spine 330 0.983 (0.971, 0.994) 0.107 - -
To enable direct comparisonwith the NHANES III BMD datameasured using Hologic QDR 100
1000 equivalents using Cross-calibration parameters for one such densitometer in the currein either sex (PN0.05). L2-L4 spineBMDappeared to beheterogeneous in
the 3 UK centres in men, but there were only 11 male UK subjects
(χ22=10.7, P=0.005, I2=81% (42%, 94%)). These estimates of between
centre and country differences in mean BMD levels were unchanged in
further sensitivity analysis that excluded centres that provided data
from b10 participants (Supplementary Table 1).
Supplementary analyses using universally standardised BMD values
(sBMD) gave similar conclusions to the analyses based on ESP-
standardised BMD values. Thus the presence of large between-centre
differences in mean BMD values persisted (Table 2, and Supplementary
Figs. 2 and 3). The sBMD values were slightly higher in magnitude than
the ESP-standardised BMD values (Table 3 in comparison with
Supplementary Table 1, or Figs. 1 and 2 in comparison with
Supplementary Figs. 1 and 2). The between-centre heterogeneityata European vs. US
D g/cm2 (95% CI) SD P for difference in means P for difference in SD
2, 0.94) 0.137 0.022 0.363
7, 0.79) 0.118 0.072 0.244
- - -
5, 0.87) 0.120 b0.0001 0.420
0, 0.72) 0.099 b0.0001 0.236
- - -
0 densitometer, the ESP standardised European datawere ﬁrst converted to Hologic QDR
nt study.
338 S. Kaptoge et al. / Bone 43 (2008) 332–339statistics in these models using sBMD values were identical to those
described above for the models using ESP-standardised BMD values.
Table 4 shows the femur data for the neck and trochanter regions as
mean and SDs for use in deriving T-scores. These, when averaged
across all centres, were compared statistically with the NHANES III
population-based US data. For women it can be seen that mean values
at both sites were signiﬁcantly lower; but at all sites and in both sexes
the SDs were very similar. Lumbar Spine L2-4 BMD was not studied in
NHANES III. Thus,when it is necessary to adjust T-scores for differences
between the young normative values in theUS and a European country
of interest, it should only be necessary to adjust the T-score by adding
or subtracting the fraction of a SD unit represented by the difference
between mean BMD values in the two countries. The expected 95%
range for such adjustments in individual European centres can be
estimated from the current ﬁndings based on the estimated standard
deviation of the between centre/country heterogeneity (τ). For
example, based on the between centre/country heterogeneity estimate
(τ) in femoral neck BMD values in males being 0.035 g/cm2 and the
pooledmean being 0.91 g/cm2, the 95% range of themean femoral neck
BMD values for individual European centres would be estimated to
be [0.91 ± 1.96⁎0.035] or 0.84 to 0.99 g/cm2. Hence the 95% range of
the adjustments to be subtracted or added to the male femoral neck
T-scores calculated based on US reference values (mean=0.93 g/cm2,
SD=0.137 g/cm2) in individual European centres would be expected to
be: (0.93 – 0.99)/0.137 to (0.93 – 0.84)/0.137 or -0.44 to +0.66 SD's.
Supplementary Fig. 3 shows the cross-sectional age-related changes in
ESP cross-calibrated DXA BMD at the femoral neck, trochanter and L2-L4
spine in the young normal males from population-based and non
population-based centres. Therewas amodest but statistically signiﬁcant
decline in femoral neck and trochanter BMD and an increase in L2-L4
spineBMDbetween theages20and30years. SupplementaryFig. 4 shows
the cross-sectional age-related changes for the young normal females.
Discussion
This is the ﬁrst large population-based study across a continent to
describe young normal values for BMD of the spine. It therefore
extends and complements the NHANES III study [4] of femoral BMD. It
was also of great interest to contrast the femoral BMD results obtained
in the US and Europe because of the world-wide use of US data as a
normative standard. The key message is that while mean European
values for BMD in the femur were sometimes different to those in the
US, the SDs were indistinguishable. This is of crucial importance when
it is desired to use T-scores because the T-score is calculated from the
difference between the measured value and the mean young normal
value divided by the young normal SD. In consequence, when it is
necessary to adjust T-scores for differences between the young
normative values in the US and a European country of interest, it
should only be necessary to adjust the T-score by adding or subtracting
the fraction of a SD unit represented by the difference between means
BMD values in the two countries.
The small but signiﬁcant differences observed in our study
between countries lead us to conclude that for public health or
therapeutic purposes it might be necessary to collect more extensive
young normal data. However this would only be of major importance
where treatment decisions are made on the basis of a ﬁxed T-score
threshold as in the UK [12]. In previous work it has been observed that
there are quite substantial between centre differences in BMD in older
populations of men and women [6] and that rates of bone loss or gain
differ between centres [13]. The between country and between centre
differences in mean BMDs described in this paper will allow the study
of whether these differences are apparently growing over time
(implying an impact of ecology on the evolution of BMD) or whether
they are constant across the range of adult ages in men and women.
This study has limitations. It was undertaken over a long time-span
(15 years), using 3 brands of DXA equipment that differed in designand performance, where cross calibration can only be imperfect.
Quality control issues are important in DXA studies, but all the staff
responsible for collecting data were experienced operators and ob-
tained their scan data according to the scanner manufacturers' recom-
mended procedures. This was a cross-sectional study, so issues relating
speciﬁcally to longitudinal studies and the measurement of small
differences in BMD over time in the same subjects do not apply. More-
over, collecting young normal data has proved challenging in the past
and our data is likely to be the best available European data-set for some
time to come. Our data regarding the effects of recruitment procedure
suggest that asking for volunteers, at least in young women, will not
always provide a fully representative sample of BMD values in the
normal population. We were limited by the availability of submitted
data in making inferences on country-speciﬁc adjustments that may be
necessary to correct T-scores calculated based on a US reference popu-
lation, since this would necessarily require a nationally representative
sampling scheme to be employed, whereas only a few centres
represented each country in our study with small numbers in some.
That the between-centre differences persisted despite the application of
universally standardised BMD values may imply that it is unlikely that
such differences were due to variations in DXA equipment, although we
cannot exclude the possibility that differences in placement of the
region of interest may be a contributing factor. For public health pur-
poses it is safer to assume that these differences are real.
In conclusion, we have provided young normal data for both sexes
for the spine for the ﬁrst time and a European database for femoral
BMD values that should allowmore conﬁdent interpretation of clinical
BMD measurements in Europeans. The origins of the fairly modest
differences between European populations in mean spine and femoral
BMD values, not addressed in this study, might reﬂect differences in
genetic background or environmental exposures.
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